Multicenter phase II study of anlotinib and toripalimab in patients with advanced soft tissue sarcoma (STS) and bone sarcoma (BS). Long-term clinical outcome assessments in patients with tenosynovial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results